Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy

Summary

There is little data regarding the impact of subclinical hyperthyroidism on coagulation metabolism in patients undergoing systemic anticoagulation therapy with coumarin derivates. In this retrospective analysis we studied 233 patients with benign thyroid disorders receiving therapeutic iodine-131, as well as concomitant systemic anticoagulation therapy (subclinical hyperthyroidism: n=178; overt hyperthyroidism: n=15; euthyroidism: n=40). Multivariate regression analyses were performed in the total study population as well as in the subgroup of patients with subclinical hyperthyroidism to identify the possible impact of several variables on anticoagulation therapy, large enough to push the International Normalized Ratio (INR) level out of the therapeutic range (INR <2.0 or >3.0).Therapy with antibiotics or nitrates was significantly associated with INR-values >3.0 in the total population, while ACE inhibitors were associated with lower incidence of INR-values <2.0. In patients with subclinical hyperthyroidism, therapy with antibiotics was predictive of INR-values >3.0, whereas therapy with thyroid suppressive drugs or TSH-values <0.1 mU/l was associated with INR-values <2.0. Moreover, in a subgroup of 40 patients with the positive history of both subclinical hyperthyroidism and euthyroidism intraindividual comparison with regard to the possible impact on anticoagulation therapy was performed which failed to show any significant differences in INR-values between the two thyroid metabolic conditions. In conclusion, subclinical hyperthyroidism seems to have no significant impact on coagulation metabolism in patients receiving anticoagulation therapy.

Keywords

Subclinical hyperthyroidism - anticoagulation therapy - coumarin derivates - benign thyroid disorders

• References

• 1 Erem C, Ersoz HÖ, Karti SS. et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 2002; 25: 345-350.
• 2 Gasse C, Hollowell J, Meier CR. et al. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005; 94: 537-543.
• 3 Thijssen HH, Soute BA, Vervoort LM. et al. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost 2004; 92: 797-802.
• 4 Hofbauer LC, Heufelder AE. Coagulation disorders in thyroid diseases. Eur J Endocrinol 1997; 136: 1-7.
• 5 Franchini M. Hemostasis and thyroid diseases revisited. J Endocrinol Invest 2004; 27: 886-892.
• 6 Loeliger EA, Esch B. The biological disappearance rate of prothrombin, factors VII, and X from plasma in hypothyroidism, hyperthyroidism, and during fever. Thromb Diathes Haemorrh 1963; 10: 267-277.
• 7 Kellet HA, Sawers JSA, Boulton FE. et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q Med J 1986; 58: 43-51.
• 8 Marongiu F, Conti M, Mameli G. et al. Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest 1988; 11: 723-725.
• 9 Rogers JS, Shane SR. Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983; 102: 444-449.
• 10 Vagenakis AG, Cote R, Miller ME. et al. Enhancement of warfarin-induced hypoprothrombinemia by thyrotoxicosis. Johns Hopkins Med J 1972; 131: 69-73.
• 11 Weintraub M, Breckinridge RT, Griner PF. The effects of dextrothyroxine on the kinetics of prothrombin activity: proposed mechanism of the potentiation of warfarin by D-thyroxin. J Lab Clin Med 1973; 81: 273-279.
• 12 Owens JC, Neely WB, Owen WR. Effect of sodium dextrothyroxine in patients receiving anticoagulants. N Eng J Med 1962; 266: 76-79.
• 13 McIntosh TJ, Brunk SF, Kolln I. et al. Increased sensitivity to warfarin in thyreotoxicosis. J Clin Invest 1970; 49: 63a-64a.
• 14 Chute JP, Ryan CP, Sladek G. et al. Excerbation of warfarin-induced anticoagultation by hyperthyroidism. Endocr Pract 1997; 03: 77-79.
• 15 Self TH, Straughn AB, Weisburst MR. Effect of hyperthyroidism on hypoprothrombinemic response warfarin. Am J Hosp Pharm 1976; 33: 387-389.
• 16 Demirkan K, Stephens MA, Newman KP. et al. Response to warfarin and other oral anticoagulants: effects of disease states. South Med J 2000; 93: 448-454.
• 17 Self T, Weisburst M, Wooten E. et al. Warfarin-induced hypoprothrombinemia. Potentiation by hyperthyroidism. JAMA 1975; 231: 1165-1166.
• 18 Woeber KA, Warner I. Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis. West L Med 1999; 170: 49-51.
• 19 Costigan DC, Freedman MH, Ehrlich RM. Potentiation of oral anticoagulant effect by L-thyroxine. Clin Pediatr 1984; 23: 172-174.
• 20 John GT, Punnoose E, Narasimhan G. et al. Enhanced action of acenocoumarin in hyperthyroidism. J Assoc Physicians India 1994; 42: 575.
• 21 Surks MI, Ortiz E, Daniels GH. et al. Subclinical thyroid disease. J Am Med Assoc 2004; 291: 228-238.
• 22 Col NF, Surks MI, Daniels GH. Subclinical thyroid disease – clinical applications. J Am Med Assoc 2004; 291: 239-243.
• 23 Schicha H, Reiners C, Moser E. et al. Subclinical thyroid disease. Nuklearmedizin 2004; 03: 69-71.
• 24 Biondi B, Palmieri EA, Lombardi G. et al. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002; 137: 904-914.
• 25 Cappola AR, Fried LP, Arnold AM. et al. Thyroid status, cardiovascular risk, and mortality in older adults. J Am Med Assoc 2006; 295: 1033-1041.
• 26 Feely J, Stevenson IH, Crooks J. Altered plasma protein binding of drugs in thyroid disease. Clin Pharmacokinet 1981; 06: 298-305.
• 27 Kurnik D, Loebstein R, Farfel Z. et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83: 107-113.
• 28 Lowenthal J, Fisher LM. The effect of thyroid function on the prothrombin time response to warfarin in rats. Experientia 1957; 13: 253-254.
• 29 van Oosterom AT, Mattie H, Hermens WT. et al. The influence of the thyroid function on the metabolic rate of prothrombin, factor VII and factor X in the rat. Thromb Haemost 1976; 35: 607-619.
• 30 Solomon HM, Schrogie JJ. Change in receptor site affinity: a proposed explanation for the potentiating effect of D-thyroxine on the anticoagulation response to warfarin. Clin Pharmacol Ther 1967; 08: 797-799.
• 31 Erem C. Blood coagulation, fibrinolytic activity, and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol 2006; 64: 323-329.
• 32 Jones CB, Fugate SE. Levofloxacin and warfarin interaction. Ann Pharmacother 2002; 36: 1554-1557.
• 33 Ravnan SL, Locke C. Levofloxacin and warfarin interaction. Pharmacotherapy 2001; 21: 884-885.
• 34 McCall KL, Scott JC, Anderson HG. Retrospective evaluation of a possible interaction between warfarin and levofloxacin. Pharmacotherapy 2005; 25: 67-73.
• 35 Foster DR, Milan NL. Potential interaction between azithromycin and warfarin. Pharmacotherapy 1999; 09: 902-908.
• 36 Shrader SP, Fermo JD, Dzikowski AL. Azithromycin and warfarin interaction. Pharmacotherapy 2004; 24: 945-949.
• 37 Visser LE, Penning-van Beest FJA, Kasbergen AAH. et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002; 88: 705-710.
• 38 Johnson MC, Wood M, Vaughn V. et al. Interaction of antibiotics and warfarin in pediatric cardiology patients. Pediatr Cardiol 2005; 26: 589-592.
• 39 Harder S, Thurmann P. Coagulation disorders in thyroid disease. Eur J Endocrinol 1997; 136: 1-7.
• 40 Meyer BH, Muller FO, Badenhorst PN. et al. Multiple doses of trandolapril do not affect warfarin pharmacodynamics. S Afr Med J 1995; 85: 768-770.
• 41 van Hecken A, Verbesselt R, Depre M. et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol 1993; 45: 291-293.
• 42 Verho M, Malerczyk V, Grotsch H. et al. Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulation agent. Pharmacotherapeutica 1989; 05: 392-399.
• 43 Dorr M, Robinson DM, Wallaschofski H. et al. Low serum thyrotropin is associated with high plasma fibri-nogen. J Clin Endocrinol Metabol 2006; 91: 530-534.
• 44 Guo Z, Raessi S, White RB. et al. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 1997; 25: 390-393.